{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:12:20Z","timestamp":1788361940741,"version":"build-2803163510"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1007\/bf02982689","type":"journal-article","created":{"date-parts":[[2008,11,3]],"date-time":"2008-11-03T17:47:35Z","timestamp":1225734455000},"page":"310-318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Adeno-Associated Virus \u2014Mediated Gene Transfer for Hemophilia B"],"prefix":"10.1007","volume":"76","author":[{"given":"Katherine A.","family":"High","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,11,1]]},"reference":[{"key":"BF02982689_CR1","unstructured":"Kazazian HH, Tuddenham EGD Antonarakis SE. Hemophilia: A: deficiency of coagulation factor VIII. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, Vol. 3. 8th ed. New York, NY: McGraw-Hill; 2001: 4367-4392."},{"key":"BF02982689_CR2","first-page":"4393","volume":"3","author":"ES Pollak","year":"2001","unstructured":"Pollak ES, High KA. Hemophilia B: factor IX deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds.The Metabolic and Molecular Basis of Inherited Disease, Vol. 3. 8th ed. New York, NY: McGraw-Hill; 2001: 4393\u20134413.","journal-title":"The Metabolic and Molecular Basis of Inherited Disease"},{"key":"BF02982689_CR3","unstructured":"HAMSTeRS: The Haemophilia A Mutation, Structure, Test and Resource Site. 2000. London, UK: MRC Clinical Sciences Centre. Available at: http:\/\/europium.csc.mrc.ac.uk."},{"key":"BF02982689_CR4","unstructured":"Haemophilia B Mutation Database, Version 11. A database of point mutations and short additions and deletions in the factor IX gene. 2002. Available at: http:\/\/www.kcl.ac.uk\/ip\/petergreen\/haem- Bdatabase.html."},{"key":"BF02982689_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/299178a0","volume":"299","author":"KH Choo","year":"1982","unstructured":"Choo KH, Gould KG, Rees DJG, Brownlee GG. Molecular-cloning of the gene for human anti-hemophilic factor-IX.Nature. 1982; 299: 178\u2013180.","journal-title":"Nature."},{"key":"BF02982689_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/312326a0","volume":"312","author":"J Gitschier","year":"1984","unstructured":"Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene.Nature. 1984; 312: 326\u2013330.","journal-title":"Nature."},{"key":"BF02982689_CR7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V76.1.254.254","volume":"76","author":"DB Brettler","year":"1990","unstructured":"Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH. Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.Blood. 1990; 76: 254\u2013256.","journal-title":"Blood."},{"key":"BF02982689_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jmv.1890060203","volume":"6","author":"RJ Gerety","year":"1980","unstructured":"Gerety RJ, Eyster ME, Tabor E, et al. Hepatitis B virus, hepatitis A virus and persistently elevated aminotransferases in hemophiliacs.J Med Virol. 1980; 6: 111\u2013118.","journal-title":"J Med Virol."},{"key":"BF02982689_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/0140-6736(90)91124-S","volume":"335","author":"M Makris","year":"1990","unstructured":"Makris M, Preston FE,Triger DR, et al. Hepatitis C antibody and chronic liver disease in haemophilia.Lancet. 1990; 335: 1117\u20131119.","journal-title":"Lancet."},{"key":"BF02982689_CR10","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.V70.3.786.786","volume":"70","author":"MV Ragni","year":"1987","unstructured":"Ragni MV, Winkelstein A, Kingsley L, Spero JA, Lewis JH. 1986 update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infection in patients with hemophilia A and B.Blood. 1987; 70: 786\u2013790.","journal-title":"Blood."},{"key":"BF02982689_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-112-5-379","volume":"112","author":"GM Rumi","year":"1990","unstructured":"Rumi GM, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels.Ann Intern Med. 1990; 112: 379\u2013380.","journal-title":"Ann Intern Med."},{"key":"BF02982689_CR12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.V78.2.285.285","volume":"78","author":"VS Blanchette","year":"1991","unstructured":"Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B.Blood. 1991; 78: 285\u2013289.","journal-title":"Blood"},{"key":"BF02982689_CR13","first-page":"437","volume":"15","author":"JM Soucie","year":"2000","unstructured":"Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.Blood. 2000; 15: 437\u2013442.","journal-title":"Blood"},{"key":"BF02982689_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","volume":"241","author":"T Lofqvist","year":"1997","unstructured":"Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patientsa long-term follow-up.J Intern Med. 1997; 241: 395\u2013400.","journal-title":"J Intern Med."},{"key":"BF02982689_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJM200008173430702","volume":"34","author":"PA Kyrle","year":"2000","unstructured":"Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism.N Engl J Med. 2000; 34: 457\u2013462.","journal-title":"N Engl J Med."},{"key":"BF02982689_CR16","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678","volume":"95","author":"Vlieg A Hylckama van","year":"2000","unstructured":"van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis.Blood. 2000; 95: 3678\u20133682.","journal-title":"Blood"},{"key":"BF02982689_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ng0595-119","volume":"10","author":"L Bi","year":"1995","unstructured":"Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene: a model for hemophilia A.Nat Genet. 1995; 10: 119\u2013121.","journal-title":"Nat Genet."},{"key":"BF02982689_CR18","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","volume":"90","author":"HF Lin","year":"1997","unstructured":"Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B.Blood. 1997; 90: 3962\u20133966.","journal-title":"Blood"},{"key":"BF02982689_CR19","doi-asserted-by":"publisher","first-page":"11563","DOI":"10.1073\/pnas.94.21.11563","volume":"94","author":"L Wang","year":"1997","unstructured":"Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy.Proc Natl Acad Sci U S A. 1997; 94: 11563\u201311566.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1055\/s-0037-1614984","volume":"79","author":"C Cameron","year":"1998","unstructured":"Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5 flanking sequence.Thromb Haemost. 1998; 79: 317\u2013322.","journal-title":"Thromb Haemost"},{"key":"BF02982689_CR21","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1182\/blood.V88.9.3451.bloodjournal8893451","volume":"88","author":"AE Mauser","year":"1996","unstructured":"Mauser AE, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs.Blood. 1996; 88: 3451\u20133455.","journal-title":"Blood"},{"key":"BF02982689_CR22","doi-asserted-by":"publisher","first-page":"10095","DOI":"10.1073\/pnas.86.24.10095","volume":"86","author":"JP Evans","year":"1989","unstructured":"Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences.Proc Natl Acad Sci U S A. 1989; 86: 10095\u201310099.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V74.1.207.207","volume":"74","author":"JP Evans","year":"1989","unstructured":"Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of a cDNA encoding canine factor IX.Blood. 1989; 74: 207\u2013212.","journal-title":"Blood"},{"key":"BF02982689_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/0378-1119(90)90290-8","volume":"86","author":"SM Wu","year":"1990","unstructured":"Wu SM, Stafford DW, Ware JL. Deduced amino acid sequence of mouse blood-coagulation factor IX.Gene. 1990; 86: 275\u2013278.","journal-title":"Gene."},{"key":"BF02982689_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.8211118","volume":"262","author":"MA Kay","year":"1993","unstructured":"Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.Science. 1993; 262: 117\u2013119.","journal-title":"Science"},{"key":"BF02982689_CR26","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.91.6.2353","volume":"91","author":"MA Kay","year":"1994","unstructured":"Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.Proc Natl Acad Sci U S A. 1994; 91: 2353\u20132357.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR27","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1073\/pnas.94.4.1426","volume":"94","author":"DD Miller","year":"1997","unstructured":"Miller DD, Alexander IE, Halbert CL, Russell DW. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.Proc Natl Acad Sci U S A. 1997; 94: 1426\u20131431.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR28","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/JVI.70.11.8098-8108.1996","volume":"70","author":"X Xiao","year":"1996","unstructured":"Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.J Virol. 1996; 70: 8098\u20138108.","journal-title":"J Virol"},{"key":"BF02982689_CR29","doi-asserted-by":"publisher","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","volume":"93","author":"PD Kessler","year":"1996","unstructured":"Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.Proc Natl Acad Sci U S A. 1996; 93: 14082\u201314087.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1094-148","volume":"8","author":"MG aplitt","year":"1994","unstructured":"aplitt MG, Leone P, Samulski RJ, et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.Nat Genet. 1994; 8: 148\u2013154.","journal-title":"Nat Genet."},{"key":"BF02982689_CR31","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1128\/JVI.72.2.1438-1445.1998","volume":"72","author":"C Summerford","year":"1998","unstructured":"Summerford C, Samulski RJ. Membrane-associated heparan sulphate proteoglycan is a receptor for adeno-associated virus type 2 virions.J Virol. 1998; 72: 1438\u20131445.","journal-title":"J Virol"},{"key":"BF02982689_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/4758","volume":"5","author":"K Qing","year":"1999","unstructured":"Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 [see comments.].Nat Med. 1999; 5: 71\u201377.","journal-title":"Nat Med."},{"key":"BF02982689_CR33","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/S0140-6736(05)77740-0","volume":"351","author":"JA Wagner","year":"1998","unstructured":"Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus.Lancet. 1998; 351: 1702\u20131703.","journal-title":"Lancet"},{"key":"BF02982689_CR34","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1089\/hum.1998.9.6-889","volume":"9","author":"JA Wagner","year":"1998","unstructured":"Wagner JA, Moran ML, Messner AH, et al. A phase I\/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.Hum Gene Ther. 1998; 9: 889\u2013909.","journal-title":"Hum Gene Ther."},{"key":"BF02982689_CR35","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1089\/104303401753153956","volume":"12","author":"ML Aitken","year":"2001","unstructured":"Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.Hum Gen Ther. 2001; 12: 1907\u20131916.","journal-title":"Hum Gen Ther."},{"key":"BF02982689_CR36","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/nm1197-1295","volume":"3","author":"FK Ferrari","year":"1997","unstructured":"Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors.Nat Med. 1997; 3: 1295\u20131297.","journal-title":"Nat Med."},{"key":"BF02982689_CR37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/8470","volume":"5","author":"C Summerford","year":"1999","unstructured":"Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents.Nat Med. 1999; 5: 587\u2013588.","journal-title":"Nat Med."},{"key":"BF02982689_CR38","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.73.5.3994-4003.1999","volume":"73","author":"W Xiao","year":"1999","unstructured":"Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1.J Virol. 1999; 73: 3994\u20134003.","journal-title":"J Virol"},{"key":"BF02982689_CR39","doi-asserted-by":"publisher","first-page":"11854","DOI":"10.1073\/pnas.182412299","volume":"99","author":"GP Gao","year":"2002","unstructured":"Gao GP, Alvira M, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.Proc Natl Acad Sci U S A. 2002; 99: 11854\u201311859.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR40","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","volume":"94","author":"R Herzog","year":"1997","unstructured":"Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV.Proc Natl Acad Sci U S A. 1997; 94: 5804\u20135809.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/sj.gt.3300680","volume":"5","author":"T Matsushita","year":"1998","unstructured":"Matsushita T. Adeno-associated virus vector can be efficiently produced without helper virus.Gene Ther. 1998; 5: 938\u2013945.","journal-title":"Gene Ther."},{"key":"BF02982689_CR42","doi-asserted-by":"publisher","first-page":"11068","DOI":"10.1073\/pnas.93.20.11068","volume":"93","author":"WF Cheung","year":"1996","unstructured":"Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX.Proc Natl Acad Sci U S A. 1996; 93: 11068\u201311073.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"BF02982689_CR43","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/10430340050015716","volume":"11","author":"R Pruchnic","year":"2000","unstructured":"Pruchnic R, Cao B, Peterson ZQ, et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers.Hum Gene Ther. 2000; 11: 521\u2013536.","journal-title":"Hum Gene Ther."},{"key":"BF02982689_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/4743","volume":"5","author":"R Herzog","year":"1999","unstructured":"Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.Nat Med. 1999; 5: 56\u201363.","journal-title":"Nat Med."},{"key":"BF02982689_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2141.1995.tb05575.x","volume":"90","author":"LW Hoyer","year":"1995","unstructured":"Hoyer LW. Why do so many haemophilia A patients develop an inhibitor?Br J Haematol. 1995; 90: 498\u2013501.","journal-title":"Br J Haematol"},{"key":"BF02982689_CR46","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1006\/mthe.2001.0491","volume":"4","author":"VR Arruda","year":"2001","unstructured":"Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.Mol Ther. 2001; 4: 586\u2013592.","journal-title":"Mol Ther."},{"key":"BF02982689_CR47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood.V97.1.130","volume":"97","author":"VR Arruda","year":"2001","unstructured":"Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX.Blood. 2001; 97: 130\u2013138.","journal-title":"Blood"},{"key":"BF02982689_CR48","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood.V97.5.1258","volume":"97","author":"AC Nathwani","year":"2001","unstructured":"Nathwani AC, Davidoff A, Hanawa H, Zhou J, Vanin EF, Nienhuis AW. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.Blood. 2001; 97: 1258\u20131265.","journal-title":"Blood"},{"key":"BF02982689_CR49","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood.V97.12.3733","volume":"97","author":"Y Ge","year":"2001","unstructured":"Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.Blood. 2001; 97: 3733\u20133737.","journal-title":"Blood"},{"key":"BF02982689_CR50","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","volume":"99","author":"JD Mount","year":"2002","unstructured":"Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.Blood. 2002; 99: 2670\u20132676.","journal-title":"Blood"},{"key":"BF02982689_CR51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/73464","volume":"24","author":"MA Kay","year":"2000","unstructured":"Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an A AV vector.Nat Genet. 2000; 24: 257\u2013261.","journal-title":"Nat Genet."},{"key":"BF02982689_CR52","unstructured":"Manno CS, Glader B, Ragni MV, et al. A phase I trial of AAV- mediated muscle directed gene transfer for hemophilia B [abstract].Thromb Haemost. 2001. Abstract OC2492."},{"key":"BF02982689_CR53","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1089\/104303402760128513","volume":"13","author":"RW Herzog","year":"2002","unstructured":"Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.Hum Gene Ther. 2002; 13: 1281\u20131291.","journal-title":"Hum Gene Ther."},{"key":"BF02982689_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/7439","volume":"5","author":"JP Greelish","year":"1999","unstructured":"Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector.Nat Med. 1999; 5: 439\u2013443.","journal-title":"Nat Med."},{"key":"BF02982689_CR55","first-page":"S157","volume":"5","author":"VR Arruda","year":"2002","unstructured":"Arruda VR, Stedman H, Nichols TC, et al. Sustained correction of hemophilia B phenotype following intravascular delivery of AAV vector to skeletal muscle.Mol Ther. 2002; 5: S157.","journal-title":"Mol Ther."},{"key":"BF02982689_CR56","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1128\/JVI.70.1.520-532.1996","volume":"70","author":"KJ Fisher","year":"1996","unstructured":"Fisher KJ, Gao G-P, Weitzman MD, DeMatteo R, Burda JF, Wilson JF. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.J Virol. 1996; 70: 520\u2013532.","journal-title":"J Virol."},{"key":"BF02982689_CR57","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1182\/blood.V91.12.4600","volume":"91","author":"H Nakai","year":"1998","unstructured":"Nakai H, Herzog R, Hagstrom JN, et al. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver.Blood. 1998; 91: 4600\u20134607.","journal-title":"Blood"},{"key":"BF02982689_CR58","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/ng0797-270","volume":"16","author":"RO Snyder","year":"1997","unstructured":"Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.Nat Genet. 1997; 16: 270\u2013276.","journal-title":"Nat Genet"},{"key":"BF02982689_CR59","first-page":"798a","volume":"96","author":"H Nakai","year":"2000","unstructured":"Nakai H, Ohashi K, Arruda V, et al. A proposed rAAV-liver directed clinical trial for hemophilia B.Blood. 2000; 96: 798a.","journal-title":"Blood"},{"key":"BF02982689_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/4751","volume":"5","author":"RO Snyder","year":"1999","unstructured":"Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.Nat Med. 1999; 5: 64\u201370.","journal-title":"Nat Med."},{"key":"BF02982689_CR61","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1006\/mthe.2000.0031","volume":"1","author":"L Wang","year":"2000","unstructured":"Wang L, Nichols TC, Read MS, Bellinger DA,Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.Mol Ther. 2000; 1: 154\u2013158.","journal-title":"Mol Ther."},{"key":"BF02982689_CR62","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/mthe.2001.0442","volume":"4","author":"RW Herzog","year":"2001","unstructured":"Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.Mol Ther. 2001; 4: 192\u2013199.","journal-title":"Mol Ther."},{"key":"BF02982689_CR63","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1089\/hum.1996.7.5-637","volume":"7","author":"T Okuyama","year":"1996","unstructured":"Okuyama T, Huber RM, Bowling W, et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha(1)-antitrypsin promoter dramatically increases expression of human alpha(1)-antitrypsin in vivo.Hum Gene Ther. 1996; 7: 637\u2013645.","journal-title":"Hum Gene Ther."},{"key":"BF02982689_CR64","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1089\/10430349950017455","volume":"10","author":"L Pastore","year":"1999","unstructured":"Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.Hum Gene Ther. 1999; 10: 1773\u20131781.","journal-title":"Hum Gene Ther."},{"key":"BF02982689_CR65","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2002-02-0589","volume":"100","author":"AC Nathwani","year":"2002","unstructured":"Nathwani AC, Davidoff AM, Hanawa H, et al. Sustained high level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.Blood. 2002; 100: 1662\u20131669.","journal-title":"Blood"},{"key":"BF02982689_CR66","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1128\/JVI.74.8.3793-3803.2000","volume":"74","author":"CH Miao","year":"2000","unstructured":"Miao CH, Nakai H, Thompson AR, et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.J Virol. 2000; 74: 3793\u20133803.","journal-title":"J Virol."},{"key":"BF02982689_CR67","unstructured":"Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. December 8-10, 1999, Bethesda, MD. National Institutes of Health Web site. Available at: http:\/\/www4.od.nih.gov\/oba\/rac\/ minutes\/1299rac.pdf."},{"key":"BF02982689_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1006\/mthe.2001.0329","volume":"3","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Chirmule N, Gao G-P, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.Mol Ther. 2001; 3: 697\u2013707.","journal-title":"Mol Ther."},{"key":"BF02982689_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1006\/mthe.2001.0330","volume":"3","author":"MA Schnell","year":"2001","unstructured":"Schnell MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.Mol Ther. 2001; 3: 708\u2013722.","journal-title":"Mol Ther."},{"key":"BF02982689_CR70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0038-1646153","volume":"70","author":"PM Mannucci","year":"1993","unstructured":"Mannucci PM. Modern treatment of hemophilia: from the shadows towards the light.Thromb Haemost. 1993; 70: 17\u201323.","journal-title":"Thromb Haemost"},{"key":"BF02982689_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T, Group MCS. An algorithm for the grading of activity in chronic hepatitis C.Hepatology. 1996; 24: 289\u2013293.","journal-title":"Hepatology"},{"key":"BF02982689_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","volume":"20","author":"French METAVIR Cooperative Study Group","year":"1994","unstructured":"French METAVIR Cooperative Study Group. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C.Hepatology. 1994; 20: 15\u201320.","journal-title":"Hepatology"},{"key":"BF02982689_CR73","doi-asserted-by":"crossref","unstructured":"Gene therapy and the germline.Nat Med. 1999; 5: 245.","DOI":"10.1038\/6429"},{"key":"BF02982689_CR74","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.294.5547.1638","volume":"294","author":"D Farber","year":"2001","unstructured":"Farber D. Gene therapy: safer and virus-free?Science. 2001; 294: 1638\u20131642.","journal-title":"Science."},{"key":"BF02982689_CR75","unstructured":"National Institutes of Health Recombinant DNA Advisory Committee minutes. June, 1998, Bethesda, MD. National Institutes of Health Web site. Available at: http:\/\/www4.od.nih.gov\/oba\/rac\/ minutes\/6-98min.htm."},{"key":"BF02982689_CR76","unstructured":"Biological Response Modifiers Advisory Committee. Issues pertaining to inadvertent germline transmission of gene transfer vectors. May 9-10, 2002, Gaithersburg, MD. Food and Drug Administration Web site. Available at: www.fda.gov\/ohrms\/dockets\/ac\/02\/ briefing\/3855B2_01.doc."},{"key":"BF02982689_CR77","unstructured":"Frankel M, Chapman A. Human inheritable genetic modifications: assessing scientific, ethical, religious, and policy issues. 2000. American Association for the Advancement of Science Web site. Available at: http:\/\/www.aaas.org\/spp\/dspp\/sfrl\/germline\/main.htm."},{"key":"BF02982689_CR78","unstructured":"Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. December 6, 2001, Bethesda, MD. National Institutes of Health Web site. Available at: http:\/\/www4.od.nih.gov\/oba."},{"key":"BF02982689_CR79","unstructured":"Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee, minutes of meeting. March 7-8, 2002, Bethesda, MD. National Institutes of Health Web site. Available at: http:\/\/www4.od.nih.gov\/oba."},{"key":"BF02982689_CR80","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1038\/sj.gt.3301541","volume":"8","author":"A Donsante","year":"2001","unstructured":"Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors.Gene Ther. 2001; 8: 1343\u20131346.","journal-title":"Gene Ther."},{"key":"BF02982689_CR81","unstructured":"Biological Response Modifiers Advisory Committee meeting #31. October 24, 2001, Gaithersburg, MD. Food and Drug Administration Web site. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/ 01\/transcripts\/3794t1.doc."},{"key":"BF02982689_CR82","unstructured":"Biological Response Modifiers Advisory Committee, 28th meeting. November 16-17, 2000, Bethesda, MD. Food and Drug Administration Web site. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/ cber00.htm."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02982689\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02982689.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T21:14:37Z","timestamp":1589058877000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02982689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["BF02982689"],"URL":"https:\/\/doi.org\/10.1007\/bf02982689","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}